9bl9: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==KIR3DL1*114 in complex with HLA-A*24:02 presenting the NEF peptide== | |||
<StructureSection load='9bl9' size='340' side='right'caption='[[9bl9]], [[Resolution|resolution]] 2.60Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9bl9]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus Human immunodeficiency virus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9BL9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9BL9 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.6Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9bl9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9bl9 OCA], [https://pdbe.org/9bl9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9bl9 RCSB], [https://www.ebi.ac.uk/pdbsum/9bl9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9bl9 ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Genetic variation in host immunity impacts the disproportionate burden of infectious diseases that can be experienced by First Nations peoples. Polymorphic human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptors (KIRs) are key regulators of natural killer (NK) cells, which mediate early infection control. How this variation impacts their responses across populations is unclear. We show that HLA-A( *)24:02 became the dominant ligand for inhibitory KIR3DL1 in First Nations peoples across Oceania, through positive natural selection. We identify KIR3DL1( *)114, widespread across and unique to Oceania, as an allele lineage derived from archaic humans. KIR3DL1( *)114(+)NK cells from First Nations Australian donors are inhibited through binding HLA-A( *)24:02. The KIR3DL1( *)114 lineage is defined by phenylalanine at residue 166. Structural and binding studies show phenylalanine 166 forms multiple unique contacts with HLA-peptide complexes, increasing both affinity and specificity. Accordingly, assessing immunogenetic variation and the functional implications for immunity are fundamental toward understanding population-based disease associations. | |||
An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania.,Loh L, Saunders PM, Faoro C, Font-Porterias N, Nemat-Gorgani N, Harrison GF, Sadeeq S, Hensen L, Wong SC, Widjaja J, Clemens EB, Zhu S, Kichula KM, Tao S, Zhu F, Montero-Martin G, Fernandez-Vina M, Guethlein LA, Vivian JP, Davies J, Mentzer AJ, Oppenheimer SJ, Pomat W, Ioannidis AG, Barberena-Jonas C, Moreno-Estrada A, Miller A, Parham P, Rossjohn J, Tong SYC, Kedzierska K, Brooks AG, Norman PJ Cell. 2024 Nov 27;187(24):7008-7024.e19. doi: 10.1016/j.cell.2024.10.005. Epub , 2024 Oct 29. PMID:39476840<ref>PMID:39476840</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: Faoro | <div class="pdbe-citations 9bl9" style="background-color:#fffaf0;"></div> | ||
[[Category: Rossjohn | == References == | ||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Human immunodeficiency virus]] | |||
[[Category: Large Structures]] | |||
[[Category: Faoro C]] | |||
[[Category: Rossjohn J]] | |||
Latest revision as of 23:21, 11 December 2024
KIR3DL1*114 in complex with HLA-A*24:02 presenting the NEF peptideKIR3DL1*114 in complex with HLA-A*24:02 presenting the NEF peptide
Structural highlights
Publication Abstract from PubMedGenetic variation in host immunity impacts the disproportionate burden of infectious diseases that can be experienced by First Nations peoples. Polymorphic human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptors (KIRs) are key regulators of natural killer (NK) cells, which mediate early infection control. How this variation impacts their responses across populations is unclear. We show that HLA-A( *)24:02 became the dominant ligand for inhibitory KIR3DL1 in First Nations peoples across Oceania, through positive natural selection. We identify KIR3DL1( *)114, widespread across and unique to Oceania, as an allele lineage derived from archaic humans. KIR3DL1( *)114(+)NK cells from First Nations Australian donors are inhibited through binding HLA-A( *)24:02. The KIR3DL1( *)114 lineage is defined by phenylalanine at residue 166. Structural and binding studies show phenylalanine 166 forms multiple unique contacts with HLA-peptide complexes, increasing both affinity and specificity. Accordingly, assessing immunogenetic variation and the functional implications for immunity are fundamental toward understanding population-based disease associations. An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania.,Loh L, Saunders PM, Faoro C, Font-Porterias N, Nemat-Gorgani N, Harrison GF, Sadeeq S, Hensen L, Wong SC, Widjaja J, Clemens EB, Zhu S, Kichula KM, Tao S, Zhu F, Montero-Martin G, Fernandez-Vina M, Guethlein LA, Vivian JP, Davies J, Mentzer AJ, Oppenheimer SJ, Pomat W, Ioannidis AG, Barberena-Jonas C, Moreno-Estrada A, Miller A, Parham P, Rossjohn J, Tong SYC, Kedzierska K, Brooks AG, Norman PJ Cell. 2024 Nov 27;187(24):7008-7024.e19. doi: 10.1016/j.cell.2024.10.005. Epub , 2024 Oct 29. PMID:39476840[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||